免疫治疗在非小细胞肺癌中的应用
The Application of Immunotherapy in Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2024.141131, PDF,   
作者: 郭永欣：青海大学研究生院，青海 西宁；姚 兵：青海大学附属医院胸外科，青海 西宁
关键词: 非小细胞肺癌；免疫治疗；免疫检查点抑制剂；Non-Small Cell Lung Cancer； Immunotherapy； Immune Checkpoint Inhibitors
摘要: 肺癌病死率、发病率在我国多种恶性肿瘤疾病中高居首位。非小细胞肺癌(non-small cell lung cancer, NSCLC)是导致肺癌患者死亡的常见临床类型，约占肺癌整体的80%。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)形式的免疫治疗在NSCLC的治疗中显示出巨大的益处，现在正被用作不可切除的局部晚期NSCLC放化疗后的巩固治疗，以及可切除NSCLC行手术切除和化疗后的辅助治疗。多项3期研究测试了针对程序性细胞死亡蛋白-1 (programmed death-1, PD-1)抗体，程序性死亡蛋白配体-1 (programmed death ligand-1, PD-L1)和细胞毒性T淋巴细胞抗原-4 (cytotox-ic-lymphocyte-associated antigen 4, CTLA-4)抗体的不同药物，联合或不联合化疗。本文通过回顾相关研究对NSCLC的免疫治疗研究进展进行综述。肺癌免疫治疗的前景正在迅速扩大，ICI已成为转移性、局部晚期和可切除NSCLC患者的标准护理治疗，OS有显著改善。
Abstract: The case fatality rate and incidence rate of lung cancer rank first among many kinds of malignant tumor diseases in China. Non-small cell lung cancer (NSCLC) is a common clinical type of death in lung cancer patients, accounting for about 80% of the overall lung cancer. Immunotherapy in the form of immune checkpoint inhibitors (immune checkpoint inhibitors, ICIs) has shown great bene-fits in the treatment of NSCLC and is now being used as consolidation therapy after unresectable lo-cally advanced NSCLC, as well as adjuvant therapy after surgical resection and chemotherapy for resectable NSCLC. Several phase 3 studies tested different agents against programmed cell death protein-1 (programmed death-1, PD-1), programmed death protein ligand-1 (programmed death ligand-1, PD-L1) and cytotoxic T lymphocyte antigen-4 (cytotoxic-lymphocyte-associated antigen 4, CTLA-4) antibodies with or in combination with chemotherapy. This review reviews the progress of immunotherapy in NSCLC by reviewing relevant studies. The promise of immunotherapy for lung cancer is rapidly expanding, and ICI has become the standard of care treatment for patients with metastatic, locally advanced and resectable NSCLC, with significant improvement in OS.
文章引用：郭永欣, 姚兵. 免疫治疗在非小细胞肺癌中的应用[J]. 临床医学进展, 2024, 14(1): 921-925. https://doi.org/10.12677/ACM.2024.141131

参考文献

[1] Tan, W.L., Jain, A., Takano, A., et al. (2016) Novel Therapeutic Targets on the Horizon for Lung Cancer. The Lancet Oncology, 17, e347-e362. [Google Scholar] [CrossRef] 
[2] Mamdani, H., Matosevic, S., Kha-lid, A.B., Durm, G. and Jalal, S.I. (2022) Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology, 13, 823618. [Google Scholar] [CrossRef] [PubMed]
[3] Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C. and Frassoldati, A. (2018) Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. American Journal of Clinical On-cology, 41, 1101-1105. [Google Scholar] [CrossRef] 
[4] Bassanelli, M., Ricciuti, B., Giannarelli, D., Cecere, F.L., Roberto, M., Giacinti, S., Barucca, V., Santarelli, M., Ruggeri, E.M., Marchetti, P., Cognet-ti, F., Gelibter, A., Cortesi, E., Chiari, R., Milella, M. and Ceribelli, A. (2021) Systemic Effect of Radiotherapy before or after Nivolumab in Lung Cancer: An Observational, Retrospective, Multicenter Study. Tumori Journal, 108, 250-257. [Google Scholar] [CrossRef] [PubMed]
[5] Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q.M., Burgio, M.A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O.A., Chiari, R., Butts, C., Wójcik-Tomaszewska, J., Coudert, B., Garassino, M.C., Ready, N., Felip, E., García, M.A., Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D.E., Czyzewicz, G., Spigel, D.R., Crino, L., Eberhardt, W.E.E., Li, A., Marimuthu, S. and Brahmer, J. (2021) Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. [Google Scholar] [CrossRef] 
[6] Anouti, B., Althouse, S., Durm, G. and Hanna, N. (2020) Prognostic Variables Associated with Improved Outcomes in Patients with Stage III NSCLC Treated with Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study from the Hoosier Cancer Research Network LUN 14-179. Clinical Lung Cancer, 21, 288-293. [Google Scholar] [CrossRef] [PubMed]
[7] Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M.J., Clingan, P., Powell, S.F., Cheng, S.Y., Bischoff, H.G., Peled, N., Grossi, F., Jennens, R.R., Reck, M., Garon, E.B., Novello, S., Ru-bio-Viqueira, B., Boyer, M., Kurata, T., Gray, J.E., Yang, J., Bas, T., Pietanza, M.C. and Garassino, M.C. (2020) Up-dated Analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreat-ed Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. [Google Scholar] [CrossRef] 
[8] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Vandormael, K., Riccio, A., Yang, J., Pietanza, M.C. and Brahmer, J.R. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Plati-num-Based Chemotherapy for Advanced Non- Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. [Google Scholar] [CrossRef] 
[9] Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., Castro Jr., G., Srimuninnimit, V., Laktionov, K.K., Bondarenko, I., Kubota, K., Lubiniecki, G.M., Zhang, J., Kush, D. and Lopes, G. (2019) KEYNOTE-042 Investigators. Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] 
[10] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R. and Brahmer, J.R. (2016) KEYNOTE-024 Investigators. Pembroli-zumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] 
[11] Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P.D., Goldschmidt Jr., J., Novello, S., Orlandi, F., Sanborn, R.E., Szalai, Z., Ursol, G., Mendus, D., Wang, L., Wen, X., McCleland, M., Hoang, T., Phan, S. and Socinski, M.A. (2021) Atezolizumab Plus Chemother-apy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpower132 Trial. Jour-nal of Thoracic Oncology, 16, 653-664. [Google Scholar] [CrossRef] [PubMed]
[12] Socinski, M.A., Özgüroğlu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Gray, J.E., Park, K., Vincent, M., Mann, H., Newton, M., Dennis, P.A. and Antonia, S.J. (2021) Durvalumab after Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 22, 549-561. [Google Scholar] [CrossRef] [PubMed]
[13] Inoue, H., Ono, A., Kawabata, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Omori, S., Wakuda, K., Kenmotsu, H., Naito, T., Murakami, H., Yasui, K., Ogawa, H., Onoe, T., Endo, M., Harada, H. and Takahashi, T. (2020) Clinical and Radia-tion Dose-Volume Factors Related to Pneumonitis after Treatment with Radiation and Durvalumab in Locally Advanced Non-Small Cell Lung Cancer. Investigational New Drugs, 38, 1612-1617. [Google Scholar] [CrossRef] [PubMed]
[14] Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Rabindran, S.K., Kasinathan, R.S., Nathan, F.E. and Ramalingam, S.S. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020-2031. [Google Scholar] [CrossRef] 
[15] Reck, M., Ciuleanu, T.-E., Dols, M.C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E. and Juan-Vidal, O. (2020) Nivolumab (NIVO)+ Ipilimumab (IPI)+ 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-Line (1L) Treatment (tx) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology, 38, 9501-9501. [Google Scholar] [CrossRef] 

为你推荐